Ontology highlight
ABSTRACT:
SUBMITTER: Chadwick L
PROVIDER: S-EPMC6244902 | biostudies-other | 2018 Nov
REPOSITORIES: biostudies-other
Chadwick Laura L Zhao Sizheng S Mysler Eduardo E Moots Robert J RJ
Current rheumatology reports 20181109 12
<h4>Purpose of review</h4>Etanercept was the first tumour necrosis factor inhibitor approved to treat rheumatoid arthritis (RA) in the United States (US) and Europe. The recent patent expiration of the etanercept originator ENBREL in Europe has facilitated the development of biosimilar products, creating the prospect of reduced treatment costs. In this article, we review the original trials for etanercept in RA to facilitate critical appraisal of biosimilar trial data.<h4>Recent findings</h4>Two ...[more]